BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

manilatimes.net · 2026-10-25

Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or after immunotherapy plus chemotherapyAn early median progression-free survival of 6.9 months was observedSignificant unmet need remains for patients who have progressed on an immunotherapy-containing regimen, with the average progression-free survival below 4 months for standard of care docetaxel Data represent the third global Phase 2 dataset for pumitamig in lung cancer and reinforce its potential to improve outcomes over current standards of care MAINZ, Germany, and PRINCETON, USA, October 25, 2026 - BioNTech SE (Nasdaq: BNTX, 'BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, 'BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer ('NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy.

TickrTrends take: Bristol Myers Squibb is advancing a combination therapy through clinical development that targets a significant patient population in non-small cell lung cancer, representing potential future revenue growth for the company. Given TickrTrends' assessment that BMY is currently overvalued, investors focused on valuation metrics should monitor whether positive clinical progress translates into meaningful earnings accretion or if current expectations already price in successful commercialization. The healthcare sector as a whole often values pipeline success heavily into stock prices before revenue materialization, which investors may want to weigh against BMY's present valuation standing.

Read the full story at manilatimes.net →